// App-Quantinova.ai

LBA2 : A Randomized Phase III Study of Temozolomide and Short-Course Radiation vs. Short-Course Radiation Alone in the Treatment of newly diagnosed Glioblastoma in Elderly Patients.

Researchers

Presenter

  • James R. Perry

Principal Investigators

  • Christopher J. O'Callaghan

  • Alba Ariela Brandes

  • Johan Menten

  • Claire Phillips

  • Michael F. Fay

  • Ryo Nishikawa

  • J. Gregory Cairncross

  • Wilson Roa

  • David Osoba

  • Arjun Sahgal

  • Hal W. Hirte

  • Wolfgang Wick

  • Florence Laigle-Donadey

  • Enrico Franceschi

  • Olivier L. Chinot

  • Chad Winch

  • Keyue Ding

  • Warren P. Mason

Medical Centers

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Azienda USL Bellaria-Maggiore Hospital, Bologna, Italy

  • Department of Radiotherapy, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • Saitama Medical University, Saitama, Japan

  • Charbonneau Cancer Institute at the University of Calgary, Calgary, AB, Canada

  • Cross Cancer Institute, Edmonton, AB, Canada

  • QOL Consulting, West Vancouver, BC, Canada

  • Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Neurology Clinic, Heidelberg, Germany

  • APHP Service de Neuro-Oncologie, Paris, France

  • Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Science, Bologna, Italy

  • Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France

  • Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

  • Japan

  • Italy

  • Germany

  • Australia

  • France

  • Belgium

Companies

  • QOL Consulting

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Temozolomide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT00482677

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved